Adcock Ingram Holdings Ltd
JSE:AIP
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| ZA |
A
|
Adcock Ingram Holdings Ltd
JSE:AIP
|
8.3B Zac |
14%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
745.9B USD |
78%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
391.9B USD |
30%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
88%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204B CHF |
27%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
182.4B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160.1B GBP |
20%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
206.1B USD |
39%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
70%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.8B USD |
9%
|
Adcock Ingram Holdings Ltd
Glance View
Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Adcock Ingram Holdings Ltd's most recent financial statements, the company has ROE of 13.8%.
You don't have any saved screeners yet